|
Obesity
|
0.200 |
Biomarker
|
disease |
RGD |
Satellite cell proliferation is reduced in muscles of obese Zucker rats but restored with loading.
|
18508911 |
2008 |
|
Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rhabdomyosarcomas are malignancies associated with a rhabdomyoblastic phenotype which can be demonstrated morphologically or by immunohistochemistry for MYOD1 and myogenin.
|
31696361 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous foamy macrophages, multinucleated Touton-type giant cells, and sheets/fascicles of smaller, often spindled macrophages largely obscured the underlying desmin, MyoD1, and myogenin-positive rhabdomyoblastic tumor.
|
30287926 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, all tumors were positive for desmin and myogenin (focal).
|
30720533 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we report 2 novel fusions (PAX3-WWTR1 and PAX3-NCOA2) in BSNS and show that MyoD1 is more sensitive than myogenin for demonstrating myogenic differentiation in this tumor.
|
30829729 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the tumor location is unusual (but head and neck seated), most of the other clinical, morphologic, immunophenotypic (focal combined expression of S100 protein, SMA, desmin, and myogenin) and oncogenic data suggest that this biphenotypic "oropharyngeal" sarcoma is closely related to the biphenotypic SNS spectrum.
|
29266774 |
2018 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
|
29973406 |
2018 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There was a significant association between high myogenin expression and ARMSs and high MyoD1 expression and spindle cell/sclerosing RMSs.
|
30098515 |
2018 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
|
29973406 |
2018 |
|
Adult Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
|
29973406 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, to identify the subtype of this sarcoma, the immunohistochemical staining of the tumor was performed with each of the various antibodies and the results are epithelial membrane antigen (-), H-caldesmon (-), desmin (+), smooth muscle actin (+), S-100 (-), myogenin (-), pan-keratin (-), and Ki-67 (positive rate: 20%).
|
28248883 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A tumor in the adrenal region with two metastases in the liver was classified as poorly differentiated sarcoma on the base of extensive immunostainings (expression of vimentin, desmin, myogenin, and CD31, no expression of inhibin, melan A).
|
27688079 |
2017 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Silencing JARID2 resulted in reduced cell proliferation coupled with myogenic differentiation, including increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representative of both the alveolar and embryonal subtypes.
|
23435416 |
2014 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amongst the transcripts differentially expressed in the RD cells, MYOD and MYOG (2 fold, p<0.05), and six MYOD downstream targets were up-regulated in RD but not C2C12 cells.
|
23717650 |
2013 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells.
|
24089019 |
2013 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells.
|
24089019 |
2013 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amongst the transcripts differentially expressed in the RD cells, MYOD and MYOG (2 fold, p<0.05), and six MYOD downstream targets were up-regulated in RD but not C2C12 cells.
|
23717650 |
2013 |
|
Adult Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells.
|
24089019 |
2013 |
|
Adult Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amongst the transcripts differentially expressed in the RD cells, MYOD and MYOG (2 fold, p<0.05), and six MYOD downstream targets were up-regulated in RD but not C2C12 cells.
|
23717650 |
2013 |
|
Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of Kirsten rat sarcoma viral oncogene [Kras(G12V)] and disruption of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16p19) in prospectively isolated satellite cells gave rise to pleomorphic rhabdomyosarcomas (MyoD-, Myogenin- and Desmin-positive), whereas introduction of the same oncogenetic hits in nonmyogenic progenitors induced pleomorphic sarcomas lacking myogenic features.
|
22135462 |
2011 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed both rhabdomyosarcoma and rhabdomyosarcomatous areas of the urothelial carcinoma were positive for myogenin, negative for cytokeratin and chromogranin stains.
|
21762516 |
2011 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed both rhabdomyosarcoma and rhabdomyosarcomatous areas of the urothelial carcinoma were positive for myogenin, negative for cytokeratin and chromogranin stains.
|
21762516 |
2011 |
|
Adult Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed both rhabdomyosarcoma and rhabdomyosarcomatous areas of the urothelial carcinoma were positive for myogenin, negative for cytokeratin and chromogranin stains.
|
21762516 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both the elbow emboli with the extratumoral foci of FRMS and the intratesticular tumor were positive for Myogenin, MyoD1, Vimentin and Desmin.
|
20701800 |
2010 |